Nebivolol protects against myocardial infarction injury via stimulation of beta 3-adrenergic receptors and nitric oxide signaling

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Zhang, Zheng ^a   Ding, Liping ^a   Jin, Zhitao ^a   Gao, Guojie ^a   Li, Huijun ^a   Zhang, Lijuan ^a   Zhang, Lina ^a   Lu, Xin ^a   Hu, Lihua ^a   Lu, Bingwei ^a   Yu, Xiongjun ^a   Hu, Taohong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; BETA 3 ADRENERGIC RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NEBIVOLOL; NEURONAL NITRIC OXIDE SYNTHASE; 3-(2-ETHYLPHENOXY)-1-(1,2,3,4-TETRAHYDRONAPHTH-1-YLAMINO)-2-PROPANOL OXALATE; BENZOPYRAN DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE; NITRIC OXIDE; NOS1 PROTEIN, MOUSE; NOS3 PROTEIN, MOUSE; PROPANOLAMINE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ARTERY; BLOOD PRESSURE; C57BL MOUSE; DRUG EFFECTS; HEART; HEMODYNAMICS; METABOLISM; MYOCARDIAL INFARCTION;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; APOPTOSIS; ARTERIES; BENZOPYRANS; BLOOD PRESSURE; ECHOCARDIOGRAPHY; ETHANOLAMINES; HEART; HEMODYNAMICS; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE III; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION;

EID: 84901349659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098179     Document Type: Article

References (24)

1. Roger VL, Jacobsen SJ, Weston SA, Goraya TY, Killian J, et al. (2002) Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med 136: 341-348. (Pubitemid 34183992)
2. Braunwald E, Bristow MR (2000) Congestive heart failure: fifty years of progress. Circulation 102: IV14-23.
3. Reiken S, Wehrens XH, Vest JA, Barbone A, Klotz S, et al. (2003) Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107: 2459-2466. (Pubitemid 36605229)
4. Brixius K, Bloch W, Ziskoven C, Bolck B, Napp A, et al. (2006) Beta3-adrenergic eNOS stimulation in left ventricular murine myocardium. Can J Physiol Pharmacol 84: 1051-1060.
5. Tavernier G, Toumaniantz G, Erfanian M, Heymann MF, Laurent K, et al. (2003) beta3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. Cardiovasc Res 59: 288-296. (Pubitemid 37272023)
6. Skeberdis VA, Gendviliene V, Zablockaite D, Treinys R, Macianskiene R, et al. (2008) beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest 118: 3219-3227.
7. Rozec B, Gauthier C (2006) beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 111: 652-673. (Pubitemid 44137382)
8. Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, et al. (2012) Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol 59: 1979-1987.
9. Varghese P, Harrison RW, Lofthouse RA, Georgakopoulos D, Berkowitz DE, et al. (2000) beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest 106: 697-703.
10. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, et al. (2001) Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103: 1649-1655. (Pubitemid 32246612)
11. Mercanoglu GO, Pamukcu B, Safran N, Mercanoglu F, Fici F, et al. (2010) Nebivolol prevents remodeling in a rat myocardial infarction model: an echocardiographic study. Anadolu Kardiyol Derg 10: 18-27.
12. Dobre D, van Veldhuisen DJ, Mordenti G, Vintila M, Haaijer-Ruskamp FM, et al. (2007) Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 154: 109-115. (Pubitemid 46920477)
13. Karter Y (2007) Nebivolol: more than a highly selective Beta blocker. Recent Pat Cardiovasc Drug Discov 2: 152-155.
14. Maffei A, Di Pardo A, Carangi R, Carullo P, Poulet R, et al. (2007) Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension 50: 652-656. (Pubitemid 47442727)
15. Zhang Z, Li S, Cui M, Gao X, Sun D, et al. (2013) Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Basic Res Cardiol 108: 333.
16. Sun D, Huang J, Zhang Z, Gao H, Li J, et al. (2012) Luteolin limits infarct size and improves cardiac function after myocardium ischemia/reperfusion injury in diabetic rats. PLoS One 7: e33491.
17. Zhang Z, Li W, Sun D, Zhao L, Zhang R, et al. (2011) Toll-like receptor 4 signaling in dysfunction of cardiac microvascular endothelial cells under hypoxia/reoxygenation. Inflamm Res 60: 37-45.
18. Sorrentino SA, Doerries C, Manes C, Speer T, Dessy C, et al. (2011) Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional beta1-blockade. J Am Coll Cardiol 57: 601-611.
19. Aragon JP, Condit ME, Bhushan S, Predmore BL, Patel SS, et al. (2011) Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. J Am Coll Cardiol 58: 2683-2691.
20. Rozec B, Noireaud J, Trochu JN, Gauthier C (2003) Place of beta 3-adrenoceptors among other beta-adrenoceptor subtypes in the regulation of the cardiovascular system. Arch Mal Coeur Vaiss 96: 905-913. (Pubitemid 37203737)
21. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H (1996) Functional beta3-adrenoceptor in the human heart. J Clin Invest 98: 556-562.
22. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, et al. (1998) The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102: 1377-1384. (Pubitemid 28467566)
23. Iwakiri Y, Tsai MH, McCabe TJ, Gratton JP, Fulton D, et al. (2002) Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol 282: H2084-2090. (Pubitemid 34663017)
24. Martin SR, Emanuel K, Sears CE, Zhang YH, Casadei B (2006) Are myocardial eNOS and nNOS involved in the beta-adrenergic and muscarinic regulation of inotropy? A systematic investigation. Cardiovasc Res 70: 97-106.